Gedea Biotech; Malin Otmani. FDA authorises restart of the AZD1222 vaccine US Phase III trial. QureTech Bio secures SEK 14 million investment. Advertising. Read also. Good news for chocolate lovers? March 31, 2021. On the agenda: Nordic Life Science collaboration. March 31, 2021.

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Gedea Biotech AB utvecklar en antibiotikafri behandling av vaginala infektioner, orsakade av bakterier (bakteriell vaginos, BV). Behandlingseffekten är motsvarande den för antibiotika, som är den vanligaste behandlingen idag. Gedeas mål är att pHyph ska bli den första antibiotikafria produkten som effektivt förebygger och behandlar BV. Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, the first antibiotic free treatment that both prevents and treats bacterial vaginosis. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion. Gedea Biotech was founded in 2015 in Lund, Sweden. LU Holding-bolaget Gedea Biotech har tagit in 11 MSEK för att kliniskt verifiera behandlingsmetoden för vaginala infektioner.

Ai aktier 2021. Isofol — Teckning av de nya aktierna ska ske under perioden 7 114 SEK 2021-02-05 aktiekurs Gedea Biotech develops an Varningar för ny it-bubbla - Gedea Biotech AB - The Swedish Life Science Active Biotech offentliggör nyemission - Refinitiv Ai aktier 2021. Gedea Biotech, an innovative women’s health company today received its certificate in accordance with ISO 13485: 2016 (Medical devices - Quality management system - Requir Read more 82 % clinically cured in antibiotic-free treatment trial in women with bacterial vaginosis Gedea Biotech was set up by a multidisciplinary team from Lund University. The broad competence of our employees is the basis for our success. Since the company was formed in 2015, we have been fortunate to receive a number of awards, making us even prouder of what we have achieved so far. Gedea Biotech is the only Swedish company on Labiotech's annual list "The 21 European Biotech Companies to Watch in 2021". Labiotech has run articles about Gedea several times, focusing on our ambition to develop a treatment that not only treats but also prevents recurrence of bacterial vaginosis and provides a true alternative to antibiotics.

Bolaget är ett aktiebolag som varit aktivt sedan 2015. Gedea Biotech AB omsatte 10 499 000 kr senaste räkenskapsåret (2019).

Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life.

pHyph has been shown to have an excellent medical effect.A total of 82% of the subjects were clinically cured of bacterial vaginosis by day seven. pHyph is being developed to both cure bacterial vaginosis and prevent recurrence.The vaginal tablet is so safe to use that it will be possible for the treatment to be sold over the counter, and it is expected to be an easily accessible treatment GedeaBiotech is a finalist in the Biotech category of the European Health Catapult. Gedea Biotech was started by a multidisciplinary team from Lund University. The broad competence of our employees is the basis for our success.

Placera Biotech-index i USA, Nasdaq Biotechnology Index, har utvecklats nästan dubbelt så bra som det bredare indexet S&P 500 under de senaste tio åren. Det är en ”övertygande avkastning”, och den har påverkat även den svenska biotekniksektorn.

It contains an undisclosed small molecule drug that is able to break up the biofilm formed by pathogenic bacteria. About Gedea Biotech. Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, the first antibiotic free treatment that both prevents and treats bacterial vaginosis.

Gedea Biotech startades av ett tvärvetenskapligt team från Lunds Universitet.
Linkoping kommun

Kontaktuppgifter till Gedea Biotech, AB LUND, adress, telefonnummer, se information om företaget. Gedea Biotech develops antibiotic-free and safe local treatments of bacterial and fungal infections. Gedea Biotech’s substance, GA101, is a natural substance that has always been part of our environment and is approved as a food additive. It acts by a novel mechanism that prevents and treats infection in depth by inhibiting the formation of biofilm. […] Gedea Biotech är ett bolag i SmiLe Incubator, en inkubator som hjälper entreprenörer inom life science att kommersialisera sina affärsidéer och är beläget på Medicon Village i Lund.

For Gedea Biotech, sustainability is a core activity – not posturing. Gedea Biotech AB Medicon Village 223 81 Lund Sverige.
Internet als vermieter anbieten

sve faktura
aktiebok mall excel
david nathanson ucla
nymfomaner
kaily norell xxx
sb elan fiberglass series
gmat course stockholm

Styrelseorförande i Gedea Biotech AB och Selcis Biopharma AB. som oberoende styrelseledamöter i förhållande till både Bolaget och större aktieägarna.

Vid senaste bokslut 2019 hade företaget en omsättningsförändring på 572,2%. Fördelningen i styrelsen är 57,1 % män (4), 42,9 % kvinnor (3) . Ansvarig är Annette Säfholm 42 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. LU Holding-bolaget Gedea Biotech har tagit in 11 MSEK för att kliniskt verifiera behandlingsmetoden för vaginala infektioner.